Turn this list into pipeline.
Pharmaceuticals Companies in Reading: 42 Active Firms (2026)
Pharmaceuticals companies in Reading develop, manufacture, import or distribute regulated medicines across the Thames Valley market.
Buying centres usually sit with quality, regulatory, procurement and clinical-supply teams, rather than a single general management buyer. The customer base is mainly business and public-healthcare-facing: wholesalers, clinical and research users, UK healthcare channels and export customers that need licence-backed supply from the Thames Valley. Engagements tend to be operational rather than speculative, covering manufacturer or wholesale distribution licensing, good manufacturing practice or good distribution practice obligations, and marketing-authorisation routes where a medicine is being placed on the market. Typical suppliers are small to mid-market operators with lean specialist teams or larger site-based workforces.
Read more
Reading has 42 trading pharmaceuticals companies in this list, making the local cohort a compact part of the Thames Valley medicines market rather than a broad manufacturing cluster. Reported employment totals 155 people, which points to lean operating teams as much as factory-scale headcount. Only 7 firms report turnover above £5M, while 6 were incorporated since 2022, so the page is likely to mix established licence-holders, specialist distributors and newer entrants building around import, development or niche supply roles.
UK human medicines sit under MHRA oversight, with obligations changing according to whether a business makes, assembles, imports, sells wholesale or places a medicine on the market. Manufacturing and import activity requires a manufacturer’s licence, good manufacturing practice and recurring site inspections; wholesale supply away from direct patient dispensing requires a wholesale distribution licence and good distribution practice. Marketing authorisation remains a separate hurdle, while public healthcare access is shaped by cost-effectiveness review. ABPI is the main trade body for research-based pharmaceutical businesses, leaving Reading operators inside a national rulebook rather than a purely local market structure.
Reading’s cohort appears likely to remain shaped by licence-holding specialists, distributors and clinical-supply adjacent businesses rather than by a wide base of integrated manufacturers. Compliance costs tend to favour operators with repeatable quality systems, documented distribution controls and enough commercial volume to carry inspection overhead. Newer entrants may stay asset-light, using partnerships for manufacturing or distribution while they test market access. Consolidation, where it occurs, is more likely to follow licensed capacity, quality assurance capability and access to healthcare or export channels than broad local demand alone.
42
Active firms
2026
7
Over £5M revenue
6
Incorporated since 2022
Key facts
About 16% of the trading cohort reports turnover above £5M (7 of 42 firms) — the rest sits below that revenue band.
14% of the cohort was incorporated since 2022 (6 firms), so a sizeable share is in its first few filing cycles.
The MHRA regulates UK human medicines, including standards, evaluation of new treatments, clinical-trial approvals, medicine licensing and pharmacovigilance.
Organisations that make, assemble or import human medicines need an MHRA manufacturer’s licence, good manufacturing practice compliance and regular site inspections.
Wholesale supply to anyone other than the patient requires a wholesale distribution licence and good distribution practice compliance.
UK business-performed pharmaceutical R&D reached £9.0 billion in 2022, equal to 0.36% of UK GDP and 18% of all UK business R&D.
UK pharmaceutical exports were valued at £25.6 billion in 2023, with the UK ranked tenth among comparator countries for this metric.
Top Reading Pharmaceuticals companies
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops and manufactures treatments for respiratory allergies, including allergy immunotherapy vaccines, diagnostic products, and emergency medicines such as adrenaline sprays, and conducts research…
Serves consumers with allergies and healthcare professionals and organisations managing respiratory allergy, allergic asthma and anaphylaxis.
Financial Health
HealthyHealthy · 5% CAGR over 1y
Location
Ridge Pharma Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsMarkets and commercialises branded prescription medicines, focusing on treatments addressing unmet medical needs. Conducts pharmaceutical market access, product promotion, and partnerships with…
Serves UK healthcare systems and professionals, including NHS market access stakeholders, clinicians and prescribers supporting patient groups with unmet medical needs.
Financial Health
StableStable · 2% CAGR over 2y
Location
Sarepta International UK Ltd.
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops precision genetic medicines for rare neuromuscular and central nervous system diseases. Conducts biotechnology research and drug development using gene therapy, RNA‑targeted exon skipping…
Serves patients with rare neuromuscular and central nervous system diseases, plus health networks, clinicians and payers involved in access to genetic medicines.
Financial Health
HealthyHealthy · Hiring · 5% CAGR over 2y
Location
AVRO Health LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed · 0% CAGR over 1y
Location
Develops and manufactures pharmaceutical medicines and medical technologies. Activities include research and production of treatments for oncology, immunology, neuroscience and cardiopulmonary…
Serves healthcare systems, clinicians and patients in oncology, immunology, neuroscience and cardiopulmonary care, plus hospitals and surgeons in cardiovascular, orthopaedic, surgery and vision…
Location
Xerimis Ltd.
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides clinical trial packaging and supply chain services for pharmaceutical studies, including labeling, blinding, warehousing, depot management, project management, and logistics for Phase 1–3…
Serves small to mid-sized pharmaceutical companies and clinical development teams running Phase 1–3 drug trials, including sponsors managing global study sites and regulated trial supply needs.
Financial Health
DistressedDistressed · 2% CAGR over 2y
Location
LOGIXX PHARMA LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops, acquires and commercialises pharmaceutical, medical device and over‑the‑counter products. Focuses on treatments for rare diseases, paediatric metabolic disorders and fertility diagnostics…
Serves healthcare professionals and patients in niche therapeutic areas, including rare-disease and paediatric metabolic medicine and fertility care, with a European market focus.
Financial Health
WeakWeak · 0% CAGR over 5y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops, acquires, markets and sells pharmaceutical products and medical treatments. Focuses on therapeutic areas including women’s health, rheumatology, ophthalmology and critical care, and…
Serves healthcare professionals, hospitals, clinics and pharmaceutical distribution partners in women’s health, rheumatology, ophthalmology, critical care and nutraceutical markets across its…
Financial Health
HealthyHealthy
Location
Develops, manufactures and distributes consumer self‑care healthcare products, including oral hygiene mouthwashes and toothpaste, women’s health treatments, glucose management products, ear care…
Serves a mix of B2C self-care consumers and B2B partners, selling through global healthcare and consumer health channels. Targets people seeking over-the-counter oral care, women’s health, glucose…
Location
ASH BIOMEDICAL INTEGRATED SERVICES LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy · Hiring · 19% CAGR over 4y
Location
Bayer Public
Develops and manufactures pharmaceutical medicines, consumer health products and agricultural inputs. Activities include research, production and sale of prescription drugs, over‑the‑counter…
Serves healthcare consumers and patients, healthcare professionals and organizations, and agricultural customers such as farmers and food producers worldwide.
Location
BIOQPHARMA CONSULTANCY LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops drug delivery systems for infusible medicines using its patented invenious platform. Produces pre‑filled, ready‑to‑use “connect‑and‑go” infusion products and partners with pharmaceutical…
Serves pharmaceutical manufacturers and commercial partners in the infusible medicines market, alongside healthcare providers, payers and patients involved in infusion-based care.
Financial Health
HealthyHealthy · Growing · 0% CAGR over 4y
Location
CHAIN Biotech
Trajectory
4y · 2020–NowFinancial sub-scores
Computed from 4 filingsDevelops microbiome-based therapeutics including oral vaccines and immunotherapies targeting the lower gastrointestinal tract. Uses a Clostridium-based drug delivery platform to engineer bacteria…
Serves pharmaceutical and biotechnology partners, oncology research organisations and clinical development collaborators in gastrointestinal and immune-oncology therapeutics.
Financial Health
StableStable · Hiring · 2% CAGR over 5y
Location
TUSCAN PHARMA LTD
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Develops and manufactures pharmaceutical medicines and medical technologies. Researches and produces treatments in areas including oncology, immunology, neuroscience and cardiopulmonary disease,…
Serves healthcare providers, hospitals, health systems, clinicians and patients across oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery and vision care.
Location
PURPLE ORCHID HEALTH LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsSupplies self-care healthcare products for genitourinary and dermatological conditions, including bladder instillation treatments, vaginal moisturisers and scale‑removing lotions. Also provides…
Serves consumers managing genito-urinary and related health conditions, including people with chronic bladder pain, cystitis, UTIs or vaginal dryness, plus parents/carers seeking cradle cap products.
Financial Health
StableStable · 0% CAGR over 4y
Location
PULSAR DEVELOPMENTS LTD.
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · -8% CAGR over 5y
Location
MONTU GROUP UK LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed · -73% CAGR over 2y
Location
Montu Pharmaceutical Ltd
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsProvides medical cannabis services including patient consultations, prescription management and dispensing of cannabis‑based medicines. Operates an online platform and pharmacy supporting access to…
Sells primarily to UK patients seeking private medical cannabis treatment for conditions such as anxiety, epilepsy, chronic illness and palliative care, and also serves UK healthcare professionals…
Financial Health
StrongStrong · Hiring · 354% CAGR over 1y
Location
TERRAMED LIMITED
Trajectory
1y · 2025–NowFinancial Health
Insufficient historyInsufficient history
Location
THE RADIANCE MEDICAL AND AESTHETIC DERMATOLOGY CLINIC LIMITED
Trajectory
4y · 2021–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
StableStable
Location
Emalex Ltd
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops pharmaceutical treatments for central nervous system disorders, with a focus on Tourette syndrome. Conducts clinical research and trials for investigational drugs, including dopamine D1…
Serves patients with Tourette syndrome and other central nervous system disorders, including paediatric and adult patients with limited approved treatment options.
Financial Health
HealthyHealthy · Growing · 0% CAGR over 4y
Location
Unlock all 42 leads
Showing 22 of 42 — +20 more with verified decision-maker contacts, live data, and CRM sync.
How Reading Pharmaceuticals companies work and how to sell to them
What they do
Reading pharmaceuticals businesses usually make money from regulated supply rather than a pure discovery bet. Revenue can come from selling finished medicines, taking wholesale margin, charging for import, assembly or batch-handling work, or providing clinical-supply and quality-controlled distribution services. Pricing tends to follow the operational unit being controlled: by order value, batch, line item, storage requirement, release milestone or project fee. A smaller set may also earn from licence-backed development work or marketing-authorisation assets, but the commercial product is still partly documentary. Buyers are paying for the medicine, the custody trail and the assurance that each regulated step can withstand audit.
Who they sell to
Most sell into healthcare-facing organisations, research and clinical users, specialist wholesalers, procurement teams and export customers that need UK-regulated supply. The active decision makers are usually heads of quality, responsible persons, regulatory affairs leads, procurement managers, supply-chain directors and, in smaller firms, finance or managing directors who carry commercial and compliance risk together. Repeat wholesale orders can move faster once supplier qualification is complete; new accounts tend to take longer where audits, tender terms, controlled storage or authorisation checks are involved. Sales are usually direct and account-managed, with public healthcare and larger channel relationships more likely to involve formal tendering or approved-supplier processes.
What they buy
Most Reading pharmaceutical firms tend to spend on systems and services that protect licence conditions, traceability and working capital. Relevant categories include quality management software, document control, batch and inventory systems, warehouse management, temperature monitoring, pharmacovigilance workflows, regulatory information management, analytics, cybersecurity and finance tools. Operational buyers may also need validation support, QA consultancy, regulatory writing, legal advice, specialist accounting, recruitment for quality and regulatory roles, and logistics services covering controlled storage or cold-chain handling. Manufacturers and assemblers add facilities, clean-area consumables, calibration, maintenance and environmental monitoring to that list, while distributors are usually more focused on stock visibility, supplier qualification and delivery evidence.
Why and how to sell to them
Commercial pressure usually comes from licence scope, audit readiness, product traceability, customer qualification and the cost of holding stock that cannot move without the right evidence. Buying intent may appear around a new or varied MHRA licence, a site move, a new distribution route, export work, a medicine line being added, a senior quality or regulatory appointment, or operational hiring. Outbound tends to work better when it is tied to a controlled process rather than a generic efficiency claim. Useful angles include reducing audit preparation, shortening release administration, improving exception handling, evidencing temperature control, or giving quality and procurement teams a clearer view of suppliers, batches and obligations.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Reading
Related directories
Frequently asked questions
How many Pharmaceuticals companies are there in the Reading?↓
What counts as a Pharmaceuticals company in this list?↓
Which are the largest Pharmaceuticals companies in the Reading?↓
What do Pharmaceuticals companies in the Reading actually do?↓
How does Reading Pharmaceuticals compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical Pharmaceuticals companies in the Reading?↓
Are these mostly new or established Pharmaceuticals companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 42 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.